|The full article is available to subscribers||Subscriber Login|
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
SEROGROUP B MENINGOCOCCAL VACCINES — Until recently, no serogroup B meningococcal vaccine was available in the US because the polysaccharide capsule of the B serogroup is only weakly immunogenic. A different meningococcal B vaccine (4CMenB; Bexsero) has been approved for use in Canada, the European Union, and Australia. In late 2013 and early 2014, the FDA and the CDC permitted the importation and investigational use of Bexsero in two outbreaks of serogroup B meningococcal disease.1
MENINGOCOCCAL DISEASE — Five major serogroups (A, B, C, Y, and W-135) of N. meningitidis cause most invasive meningococcal... more
- In brief: Prevention of meningococcal B disease. Med Lett Drugs Ther 2013; 55:97.
- AC Cohn et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2):1.
- Menactra: A meningococcal conjugate vaccine. Med Lett Drugs Ther 2005; 47:29.
- A new conjugate meningococcal vaccine (Menveo). Med Lett Drugs Ther 2010; 52:59.
- In brief: Meningococcal vaccine for infants. Med Lett Drugs Ther 2013; 55:92.
- DA Adams et al. Summary of notifiable diseases-United States, 2012. MMWR Morb Mortal Wkly Rep 2014; 61(53):1.
- PC Richmond et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597.
- LK McNeil et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 2013; 77:234.